Ocugen (OCGN)
(Delayed Data from NSDQ)
$1.60 USD
-0.13 (-7.51%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.61 +0.01 (0.63%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Brokerage Reports
Ocugen, Inc. [OCGN]
Reports for Purchase
Showing records 41 - 60 ( 121 total )
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN Delays Due to Manufacturing Issue; PT Lowered to $7; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Update - Eye Programs Progress but COVAXIN Stalls, PT Drops to $4
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
ARVO, the Global Ophthalmology Meeting Begins on Sunday, May 1st in Denver
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Stock Struggles to Hold Share Gains Given COVAXIN''s Manufacturing Overhang
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Panels & Fireside Chats at Our 34th Annual ROTH Conference
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN''s Commercial Plans Hit Another Snag- FDA Denies Pediatric EUA
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN Clinical Study Initiation Imminently; Lower PT to $8; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Update - Impressive Progress But More Time Needed To Build Conviction
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
FDA Lifts Clinical Hold on IND For COVAXIN - So What''s Next?
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
FDA Lifts Clinical Hold; Potential COVAXIN BLA Filing in 1H2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From our KOL Call on Vaccines and Therapies Targeting COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Translational Immunological Data Support COVAXIN?s Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1/2 Gene Therapy Study for Retinitis Pigmentosa to Begin in 1Q22
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN Has Another Bridge To Cross - U.S. IND Placed on Clinical Hold
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z